Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.

NCT Number	NCT07407582
Lead Sponsor	University of Arizona Collaborators: Fennec Pharma
Conditions	Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer
Enrollment	25 participants
Start Date	2026-05-18
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-18